Update on taxane development: new analogs and new formulations - Wikidata - awgldk - TriplyDB

Update on taxane development: new analogs and new formulations

Update on taxane development: new analogs and new formulations

http://www.wikidata.org/entity/Q36470377

about

Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Epothilones: From discovery to clinical trials STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles induces proliferation inhibition and apoptosis in ovarian cancer cells Cytotoxic effects of docetaxel as a candidate drug of drug-eluting stent on human umbilical vein endothelial cells and the signaling pathway of cell migration inhibition, adhesion delay and shape change Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment.Anticancer Alkaloids from Trees: Development into Drugs.Ephrin type‑A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3‑kinase/Akt signalling pathway The newly synthesized anticancer drug HUHS1015 is useful for treatment of human gastric cancer The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.Designing and Testing of Novel Taxanes to Probe the Highly Complex Mechanisms by Which Taxanes Bind to Microtubules and Cause Cytotoxicity to Cancer Cells Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.Medicinal Plants: A Potential Source of Compounds for Targeting Cell Division.Can Some Marine-Derived Fungal Metabolites Become Actual Anticancer Agents?Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Identifying therapeutic targets in gastric cancer: the current status and future direction Septin cooperation with tubulin polyglutamylation contributes to cancer cell adaptation to taxanes Therapeutic surfactant-stripped frozen micelles.Taxane anticancer agents: a patent perspective.Adverse drug reaction profile of microtubule-damaging antineoplastic drugs: A focused pharmacovigilance study in India.TXR1 and TSP1 expression varies by the molecular subtypes of breast cancer patients who received previous docetaxel-based first-line chemotherapy.Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer.Targeting microtubules by natural agents for cancer therapy.Anti-leukemia effects of the novel synthetic 1-benzylindole derivative 21-900 in vitro and in vivo High throughput screening of natural products for anti-mitotic effects in MDA-MB-231 human breast carcinoma cells Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: in vitro and in vivo evaluation.Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities.Nanodrug delivery in reversing multidrug resistance in cancer cells.Synthesis and Evaluation of Paclitaxel-Loaded Gold Nanoparticles for Tumor-Targeted Drug Delivery.Recombinant adenovirus expressing hIFN-λ1 inhibits gastric adenocarcinoma cell line SGC-7901 proliferation Brain-targeted delivery of docetaxel by glutathione-coated nanoparticles for brain cancer.Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases.Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.Marketed drugs used for the management of hypercholesterolemia as anticancer armament.Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples.Cascade Metathesis Reactions for the Synthesis of Taxane and Isotaxane Derivatives.

P2860

Q26749037-DD5C76FE-1AB0-4F5C-B458-E91D03933A3D Q26830913-E64AA1C4-5F56-4419-AFC6-B0DB182DBDCB Q27005747-BB298F41-126A-4304-84AC-19580ECCC32E Q28536340-5A1C518B-4658-4B99-892A-8362B27639A6 Q30421395-E0F4ED18-2980-4F9B-BDEE-8208AE68EE62 Q33762904-3E27B9F9-B59C-462F-A3A5-4C63D28B59C1 Q34005665-BB290349-3DE6-4907-9548-0DE0CC0FE6AB Q34549113-330798A9-0CB5-44E4-9970-9246ABBB1E82 Q34673530-E5F74B11-B27F-47D0-B42B-2A4341A16FBE Q35123190-BD8DAD28-98A1-4AE9-BA28-85C0FEA260AA Q35140489-12D7AADB-CA07-4A6D-8864-32D6ABDD4FFC Q35656185-B9E1F859-AEFA-4498-A7E8-21FADD4B8C67 Q35706804-1942F13D-019B-47B8-A53E-0E343F6C7ACE Q35746819-58CC97C1-BD12-499D-B16A-4B24251A093A Q35790810-A7EC9AC6-0DAC-4864-A320-D5C7E48E9CD9 Q36340055-4C39485B-5782-431A-8552-DF9D870106F3 Q36372894-D20F0BA7-9582-493A-80CF-F5B7A1907F58 Q36398732-E1CC0DA6-3383-4F62-AC3E-12259EF9AFC1 Q36546567-9E8D020E-3DDE-467C-9F2E-D33D3E87EBCA Q36919868-C44E7AF5-B684-41B0-A582-1EA8A67A0E43 Q37087888-B5ACC5FF-39A0-4AFA-BE40-CE441A00AE19 Q37311957-B518F147-45FD-468B-91DF-42961E56076C Q37347204-19E21536-0E5F-46CC-9F77-177FA8F298EE Q37577579-A83B6627-4C1E-43EA-BC28-2B3C043BC07E Q37623838-F8EFFB1C-A5F7-4808-A415-7005C336E66B Q37633285-587D137D-C41A-45B5-AD1B-F1D43711C8F6 Q37641834-D48665A1-F629-48F0-9729-6344220DA61D Q37683970-77F92169-C6D6-4D77-9F67-BDDE44BF2AE8 Q38183686-1BB4429C-FEDB-4F61-89E5-7208E55F63A3 Q38234908-9BB2C12B-5E9A-40F4-AE0D-C2120535DF15 Q38740409-534FBBEE-FE55-47AE-AD98-A86767C97D32 Q38794769-66077C67-F2EE-4BAC-A35B-8B8F6926AE92 Q38964871-84981616-8B46-4E7B-BC99-1AF20D32AD35 Q38999750-4145BDF2-2659-4EDF-B34E-964E8D88CB79 Q39011125-56EB9734-1A0C-4AB3-A98C-B28A96C199FB Q39577399-0E71B4D5-2281-42D0-BF7A-69185967C133 Q41080847-B8D9647C-6B86-4CFD-B047-6A2330AF3DAE Q41897007-65936DEF-010B-4654-B24D-A68F5899F684 Q41937519-85D136EC-A3F8-46F8-BF18-32607D032F10 Q42362195-803CDF87-C887-4ED3-9995-CDEFFFE813BD

P2860

Update on taxane development: new analogs and new formulations

http://www.wikidata.org/entity/Q36470377

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Update on taxane development: new analogs and new formulations

@ast

Update on taxane development: new analogs and new formulations

@en

type

label

Update on taxane development: new analogs and new formulations

@ast

Update on taxane development: new analogs and new formulations

@en

prefLabel

Update on taxane development: new analogs and new formulations

@ast

Update on taxane development: new analogs and new formulations

@en

P1433

Q36470377-0D3A5678-7F15-4835-80A8-D7F4F66147B5

P1476

Q36470377-29DF93C7-FE9B-4CF1-A703-796F9F33E326

P2093

Q36470377-CB056E19-39D7-4589-99D5-861747101A8E

Q36470377-CED01012-1154-43B0-A305-22379B6956EA

P2860

Q36470377-079390DA-68FA-4279-9A14-4C9B973C6504

Q36470377-129DFC3A-D597-4F4B-9F22-4F44806D3C14

Q36470377-143954D1-B9C3-45E2-AEAD-64ED5B55340E

Q36470377-1BF1899D-82D8-4D55-9774-2D9A19A39441

Q36470377-233B61DE-9254-4FAC-A2DA-360234363CCC

Q36470377-28E012B3-B5AF-4773-922A-6A155B9D4688

Q36470377-2C551EF4-7632-489B-BAF2-53D320122563

Q36470377-3352CF09-1992-4EF6-9003-0FF987FAE9EC

Q36470377-36AA76DC-4B63-40B0-BE54-C9D40C392D1C

Q36470377-3A682D1B-DF13-4DFD-AC3E-A8E4DE731DC4

P304

Q36470377-41851335-3121-4865-A571-FC2EB957C690

P31

Q36470377-484394C7-EF84-4F60-8EBC-7DA8748A5E11

Q36470377-757AACAD-35C1-4F3A-A3A5-A8D597E5B75C

P356

Q36470377-739AEC57-5DC3-4627-8B5C-FEDE747C5477

P407

Q36470377-630A50E5-E190-465A-88C8-B8FBFD2E77C2

P478

Q36470377-F07632F3-FE91-4764-A279-84BA70B685B2

P577

Q36470377-786A4F30-9FDA-4777-B7E6-341CD94F89FE

P698

Q36470377-D936E7B0-9A15-44FF-8CCD-465BBB49960C

P921

Q36470377-01EEB7A4-3BC7-41E7-83C7-420B45667241

Q36470377-C5DA2B68-4E7E-4D2B-90A0-796FF1FF0B08

P932

Q36470377-0274AF51-650A-4929-9700-2FFEC3116FE1

P356

P1433

Drug Design, Development and Therapy

P1476

Update on taxane development: new analogs and new formulations

@en

P2093

Jean A Yared

http://www.w3.org/2001/XMLSchema#string

Katherine H R Tkaczuk

http://www.w3.org/2001/XMLSchema#string

P2860

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data.

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes.

Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer.

Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.

P304

371-384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S28997

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23251087

http://www.w3.org/2001/XMLSchema#string

P921

P932

3523563

http://www.w3.org/2001/XMLSchema#string